Why Treatment Fails in Type 2 Diabetes

Erik Renström and colleagues discuss a new mouse study that explores the mechanism behind the secondary failure of sulfonylurea treatment.

• Publication year

  2008

• Venue

  PLoS Medicine

• Publication date

  2008-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1371/journal.pmed.0050215PMID 18959474PMCID 2573917
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chronic Antidiabetic Sulfonylureas In Vivo: Reversible Effects on Mouse Pancreatic β-Cells

  2008cited by this paper
• Beta-cell apoptosis in type 2 diabetes: quantitative and functional consequences.

  2008cited by this paper
• Genome-wide association scans for Type 2 diabetes: new insights into biology and therapy.

  2007cited by this paper
• Hyperinsulinism in mice with heterozygous loss of KATP channels

  2006cited by this paper
• Sulfonylurea Induced β-Cell Apoptosis in Cultured Human Islets

  2005cited by this paper
• Sulfonylurea Induced-Cell Apoptosis in Cultured Human Islets

  2004cited by this paper
• Sulfonylurea Receptor Type 1 Knock-out Mice Have Intact Feeding-stimulated Insulin Secretion despite Marked Impairment in Their Response to Glucose*

  2002cited by this paper
• Sur1 Knockout Mice A MODEL FOR K ATP CHANNEL-INDEPENDENT REGULATION OF INSULIN SECRETION*

  2000cited by this paper
• Sur1 Knockout Mice

  2000cited by this paper
• UKPDS 26: sulphonylurea failure in non‐insulin‐dependent diabetic patients over six years

  1998cited by this paper
• The U.K. Prospective Diabetes Study: A review

  1998cited by this paper
• Defective insulin secretion and enhanced insulin action in KATP channel-deficient mice.

  1998cited by this paper
• Correlating structure and function in ATP-sensitive K+ channels.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Opposite effects of tolbutamide and diazoxide on the ATP-dependent K+ channel in mouse pancreatic β-cells

  1986cited by this paper

• Classifying Biophysical Subpopulations of Insulin Secretory Granules using Quantitative Whole Cell Structure Analysis

  2025cites this paper
• Pharmacological effect of ZYGK1, a novel glucokinase activator, in hyperglycemic and sulfonylurea-resistant type 2 diabetes in mice models.

  2025cites this paper
• Vitamin D Fortification: A Promising Approach to Overcome Drug Resistance and Tolerance in Therapeutic Interventions

  2024cites this paper
• Should Glucokinase be Given a Chance in Diabetes Therapeutics? A Clinical-Pharmacological Review of Dorzagliatin and Lessons Learned So Far

  2024cites this paper
• Enhanced Insulin Production From Porcine Islets: More Insulin, Less Islets

  2024cites this paper
• The Role of G Protein–Coupled Receptors and Receptor Kinases in Pancreatic β-Cell Function and Diabetes

  2024cites this paper
• Metformin and sitagliptin fixed combination as the optimal choice in solving current problems in the type 2 diabetes mellitus treatment

  2023cites this paper
• Metformin and sitagliptin fixed combination as the optimal choice in solving current problems in the type 2 diabetes mellitus treatment

  2023cites this paper
• Pancreatic islet protection at the expense of secretory function involves serine-linked mitochondrial one-carbon metabolism

  2023cites this paper
• Identification of Effective and Nonpromiscuous Antidiabetic Drug Molecules from Penicillium Species

  2022cites this paper
• Targeting the insulin granule for modulation of insulin exocytosis.

  2021cites this paper
• Generating Ins2+/-/miR-133aTg Mice to Model miRNA-Driven Cardioprotection of Human Diabetic Heart.

  2021cites this paper
• Ion channels as therapeutic targets for type 1 diabetes mellitus.

  2020cites this paper
• Beta-cell function in type 2 diabetic patients who failed to maintain good glycemic status with a combination of maximum dosages of metformin and sulfonylurea Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

  2019cites this paper
• Thematic assessment of current clinical oral implant research and its prevalence in daily clinical practice / submitted by Dr. Vesela Valkova

  2019cites this paper
• Beta-cell function in type 2 diabetic patients who failed to maintain good glycemic status with a combination of maximum dosages of metformin and sulfonylurea

  2019cites this paper
• Change in Static Postural Stability after a Home‐based Exercise Program in Persons with Idiopathic Parkinson’s Disease ‐ A Randomized Control Study

  2019cites this paper
• Sixty Years of Drug Discovery for Type 2 Diabetes: Where Are We Now?

  2019cites this paper
• Efficacy and Safety of Teneligliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: A Randomized, Double-blind Study

  2018cites this paper
• When metformin is not enough: Pros and cons of SGLT2 and DPP‐4 inhibitors as a second line therapy

  2018cites this paper
• Effects of Reg3 Delta Bioactive Peptide on Blood Glucose Levels and Pancreatic Gene Expression in an Alloxan-Induced Mouse Model of Diabetes.

  2016cites this paper
• EVALUATION OF ANTIDIABETIC POTENTIAL OF METHANOLIC EXTRACT OF BENINCASA HISPIDA IN STREPTOZOTOCIN INDUCED DIABETIC RATS

  2015cites this paper
• COMPUTATIONAL STUDY OF ANTIDIABETIC ACTIVITIES OF BIOACTIVE COMPOUNDS IN ZINGIBER OFFICINALE

  2014cites this paper